结合改良Kadish分期及Hyams分级评估嗅神经母细胞瘤预后的预测模型回顾性分析

赖银妍; 林腾蛟; 江丽洁; 邓洁; 左可军; 张玉; 史剑波

doi:10.13201/j.issn.1001-1781.2019.07.006

结合改良Kadish分期及Hyams分级评估嗅神经母细胞瘤预后的预测模型回顾性分析

- 1 中山大学附属第一医院耳鼻咽喉医院耳鼻咽喉科(广州, 510800);
- 2 中山大学肿瘤防治中心

详细信息

通讯作者: 史剑波,E-mail:tsjbent@163.com

中图分类号: R739.6

收稿日期: 2018-11-09

New system combining Hyams grading system and modified Kadish stage to evaluate the progress of esthesioneuroblastoma

- 1 Department of Otolaryngology, Otorhinolaryngology Hospital, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510800, China;
- 2 Sun Yat-sen University Cancer Center

More Information

Corresponding author: SHI Jian-bo, E-mail: tsjbent@163.com

Received Date: 09 November 2018

摘要

摘要: 目的:建立一个相对准确而简易的模型来预测嗅神经母细胞瘤(ENB)的预后。方法:回顾性分析31例ENB患者的临床资料和病理切片;耳鼻咽喉科医师和影像学专家通过使用改良Kadish分期评估患者病情及临床分期;由2位病理学家使用Hyams评分系统对病理特征进行回顾性评分。最后,用Kaplan-Meier法评估ENB患者的临床资料、病理特征及临床预后的关系。结果:结合Hyams评分系统和改良Kadish分期2个分期系统评估病情,能更准确地判断ENB的预后,当分数超过6分,患者预后不良,平均生存期为(24.67±32.22)个月;最终的分数若达到4、5、6、7、8分,肿瘤转移率分别为14.3%、16.7%、33.3%、50.0%、100.0%。结论:结合使用Hyams分级系统和改良Kadish分期系统评估病情,可更准确且简易地评价ENB的预后。
- Hyams分级系统 /
- 改良Kadish分期系统 /
- 预后 /
- 嗅神经母细胞瘤
Abstract: Objective: Esthesioneuroblastoma(ENB) is a sinonasal rare tumor, and the assessment on the prognosis have not been used with on consensus, our study aims to set an accuracy indicator to predict the outcomes of ENB. Method: A retrospective review was performed on 31 ENB patients. We collected 31 patients with ENB and reviewed the clinical data and pathological slides; modified Kadish stages were evaluated by otolaryngologist and imaging specialist; Hyams grading system were confirmed by two pathologists, who reviewed and paid attention to the pathological characteristics of Hyams grading system. Finally, the relation among the clinical data, pathological features and clinical outcome of these 31 ENB were analyzed by Kaplan-Meier method. Result: The Hyams grading system and modified Kadish stage were considered together seemed to evaluate the prognosis of ENB more accurately, when the scores over 6 points, the patients had the poor prognosis with the mean median survival months of 24.67±32.22, compared with the scores under 6 and the final scores reached at 4, 5, 6, 7, 8, the tumor metastasis rates were 14.3%, 16.7%, 33.3%, 50.0%, 100.0% respectively. Conclusion: Taking the Hyams grading system and modified Kadish stage into consideration, which may evaluate the prognosis of ENB more accurately.
- Hyams grading system /
- modified Kadish stage /
- prognosis /
- esthesioneuroblastoma

HTML全文

参考文献(10)

[1]	BRADLEY P J, JONES N S, ROBERTSON I.Diagnosis and management of esthesioneuroblastoma[J].Curr Opin Otolaryngol Head Neck Surg, 2003, 11:112-118.
[2]	LUND V J, HOWARD D, WEI W, et al.Olfactory neuroblastoma:past, present, and future[J]?Laryngoscope, 2003, 113:502-504.
[3]	SONG C M, WON T B, LEE C H, et al.Treatment modalities and outcomes of olfactory neuroblastoma[J].Laryngoscope, 2012, 122:2389-2395.
[4]	DULGUEROV P, ALLAL A S, CALCATERRA T C.Esthesioneuroblastoma:a meta-analysis and review[J].Lancet Oncol, 2001, 2:683-687.
[5]	GALLAGHER K K, SPECTOR M E, PEPPER J P, et al.Esthesioneuroblastoma:updating histologic grading as it relates to prognosis[J].Ann Otol Rhinol Laryngol, 2014, 123:353-358.
[6]	SAADE R E, HANNA E Y, BELL D.Prognosis and biology in esthesioneuroblastoma:the emerging role of Hyams grading system[J].Curr Oncol Rep, 2015, 17:423-425.
[7]	JETHANAMEST D, MORRIS L G, SIKORA A G, et al.Esthesioneuroblastoma:apopulation-based analysis of survival and prognostic factors[J].Arch Otolaryngol Head Neck Surg, 2007, 133:276-280.
[8]	NALAVENKATA S B, SACKS R, ADAPPA N D, et al.Olfactory neuroblastoma:fate of the neck——a longterm multicenter retrospective study[J].Otolaryngol Head Neck Surg, 2016, 154:383-385.
[9]	MALOUF G G, CASIRAGHI O, DEUTSCH E, et al.Low-and high-grade esthesioneuroblastomas display a distinct natural history and outcome[J].Eur J Cancer, 2013, 49:1324-1334.
[10]	YIN Z Z, GAO L, LUO J W, et al.Long-term outcomes of patients with esthesioneuroblastomas:A cohort from a single institution[J].Oral Oncol, 2016, 53:48-53.